Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alectinib - Roche

Next Previous
Drug Profile

Alectinib - Roche

Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802

Latest Information Update: 01 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; Anaplastic large cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Non-small cell lung cancer
  • Preregistration Solid tumours
  • Phase I/II Brain cancer; Thyroid cancer

Most Recent Events

  • 21 Oct 2025 Efficacy data from a phase III ALEX trial in Non-Small Cell Lung Cancer released by Chugai Pharmaceutical
  • 30 Jun 2025 Preregistration for ALK fusion/rearrangement positive Solid tumours (Inoperable/Unresectable, Late-stage disease, Recurrent) in Japan (PO) (Chugai Pharmaceutical pipeline, November 2025)
  • 30 May 2025 Efficacy and adverse events data from a phase I/II trial in solid tumor presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top